{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:59:28Z","timestamp":1791662368079,"version":"4.3.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Science, Technology, and Innovation Commission of Shenzhen Municipality","award":["20200925174802001"],"award-info":[{"award-number":["20200925174802001"]}]},{"name":"Shenzhen Medical Research Fund","award":["B2402039"],"award-info":[{"award-number":["B2402039"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-05659-w","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T11:21:23Z","timestamp":1751368883000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["ZFHX3 is integral to androgen\/AR signaling involving protein association with AR in prostate cancer cells"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0887-7539","authenticated-orcid":false,"given":"Xing","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"A","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2349-5782","authenticated-orcid":false,"given":"Jin-Tang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"5659_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17\u201348. https:\/\/doi.org\/10.3322\/caac.21763 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"5659_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jncc.2022.02.002","volume":"2","author":"R Zheng","year":"2022","unstructured":"Zheng, R. et al. Cancer incidence and mortality in china, 2016. J. Natl. Cancer Cent. 2, 1\u20139. https:\/\/doi.org\/10.1016\/j.jncc.2022.02.002 (2022).","journal-title":"J. Natl. Cancer Cent."},{"key":"5659_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"5659_CR4","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1210\/er.2002-0032","volume":"25","author":"CA Heinlein","year":"2004","unstructured":"Heinlein, C. A. & Chang, C. Androgen receptor in prostate cancer. Endocr. Rev. 25, 276\u2013308. https:\/\/doi.org\/10.1210\/er.2002-0032 (2004).","journal-title":"Endocr. Rev."},{"key":"5659_CR5","doi-asserted-by":"publisher","unstructured":"Rebello, R. J. et al. Prostate cancer. Nat. Reviews Disease Primers. 7 https:\/\/doi.org\/10.1038\/s41572-020-00243-0 (2021).","DOI":"10.1038\/s41572-020-00243-0"},{"key":"5659_CR6","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/endrev\/bnab002","volume":"42","author":"K Desai","year":"2021","unstructured":"Desai, K., McManus, J. M. & Sharifi, N. Hormonal therapy for prostate cancer. Endocr. Rev. 42, 354\u2013373. https:\/\/doi.org\/10.1210\/endrev\/bnab002 (2021).","journal-title":"Endocr. Rev."},{"key":"5659_CR7","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl. J. Med. 364, 1995\u20132005. https:\/\/doi.org\/10.1056\/NEJMoa1014618 (2011).","journal-title":"N Engl. J. Med."},{"key":"5659_CR8","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James, N. D. et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl. J. Med. 377, 338\u2013351. https:\/\/doi.org\/10.1056\/NEJMoa1702900 (2017).","journal-title":"N Engl. J. Med."},{"key":"5659_CR9","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1126\/science.1168175","volume":"324","author":"C Tran","year":"2009","unstructured":"Tran, C. et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324, 787\u2013790. https:\/\/doi.org\/10.1126\/science.1168175 (2009).","journal-title":"Science"},{"key":"5659_CR10","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","volume":"378","author":"M Hussain","year":"2018","unstructured":"Hussain, M. et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl. J. Med. 378, 2465\u20132474. https:\/\/doi.org\/10.1056\/NEJMoa1800536 (2018).","journal-title":"N Engl. J. Med."},{"key":"5659_CR11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41585-021-00438-4","volume":"18","author":"KT Schmidt","year":"2021","unstructured":"Schmidt, K. T., Huitema, A. D. R., Chau, C. H. & Figg, W. D. Resistance to second-generation androgen receptor antagonists in prostate cancer. Nat. Rev. Urol. 18, 209\u2013226. https:\/\/doi.org\/10.1038\/s41585-021-00438-4 (2021).","journal-title":"Nat. Rev. Urol."},{"key":"5659_CR12","doi-asserted-by":"publisher","first-page":"26840","DOI":"10.1074\/jbc.270.45.26840","volume":"270","author":"Y Miura","year":"1995","unstructured":"Miura, Y. et al. Cloning and characterization of an ATBF1 isoform that expresses in a neuronal differentiation-dependent manner. J. Biol. Chem. 270, 26840\u201326848. https:\/\/doi.org\/10.1074\/jbc.270.45.26840 (1995).","journal-title":"J. Biol. Chem."},{"key":"5659_CR13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng1528","volume":"37","author":"X Sun","year":"2005","unstructured":"Sun, X. et al. Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nat. Genet. 37, 407\u2013412. https:\/\/doi.org\/10.1038\/ng1528 (2005).","journal-title":"Nat. Genet."},{"key":"5659_CR14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nature11125","volume":"487","author":"CS Grasso","year":"2012","unstructured":"Grasso, C. S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239\u2013243. https:\/\/doi.org\/10.1038\/nature11125 (2012).","journal-title":"Nature"},{"key":"5659_CR15","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/jcmm.17125","volume":"26","author":"X Fu","year":"2022","unstructured":"Fu, X. et al. AR imposes different effects on ZFHX3 transcription depending on androgen status in prostate cancer cells. J. Cell. Mol. Med. 26, 800\u2013812. https:\/\/doi.org\/10.1111\/jcmm.17125 (2022).","journal-title":"J. Cell. Mol. Med."},{"key":"5659_CR16","doi-asserted-by":"publisher","first-page":"4863","DOI":"10.1038\/s41467-023-39858-8","volume":"14","author":"S Ito","year":"2023","unstructured":"Ito, S. et al. Androgen receptor binding sites enabling genetic prediction of mortality due to prostate cancer in cancer-free subjects. Nat. Commun. 14, 4863. https:\/\/doi.org\/10.1038\/s41467-023-39858-8 (2023).","journal-title":"Nat. Commun."},{"key":"5659_CR17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.neo.2014.05.001","volume":"16","author":"X Sun","year":"2014","unstructured":"Sun, X. et al. Deletion of atbf1\/zfhx3 in mouse prostate causes neoplastic lesions, likely by Attenuation of membrane and secretory proteins and multiple signaling pathways. Neoplasia 16, 377\u2013389. https:\/\/doi.org\/10.1016\/j.neo.2014.05.001 (2014).","journal-title":"Neoplasia"},{"key":"5659_CR18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.jgg.2015.06.004","volume":"42","author":"X Sun","year":"2015","unstructured":"Sun, X. et al. Additive effect of Zfhx3\/Atbf1 and Pten deletion on mouse prostatic tumorigenesis. J. Genet. genomics = Yi Chuan Xue Bao. 42, 373\u2013382. https:\/\/doi.org\/10.1016\/j.jgg.2015.06.004 (2015).","journal-title":"J. Genet. genomics = Yi Chuan Xue Bao"},{"key":"5659_CR19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41389-019-0138-y","volume":"8","author":"Q Hu","year":"2019","unstructured":"Hu, Q. et al. ZFHX3 is indispensable for erbeta to inhibit cell proliferation via MYC downregulation in prostate cancer cells. Oncogenesis 8, 28. https:\/\/doi.org\/10.1038\/s41389-019-0138-y (2019).","journal-title":"Oncogenesis"},{"key":"5659_CR20","doi-asserted-by":"publisher","first-page":"32801","DOI":"10.1074\/jbc.M110.128330","volume":"285","author":"XY Dong","year":"2010","unstructured":"Dong, X. Y. et al. ATBF1 inhibits Estrogen receptor (ER) function by selectively competing with AIB1 for binding to the ER in ER-positive breast cancer cells. J. Biol. Chem. 285, 32801\u201332809. https:\/\/doi.org\/10.1074\/jbc.M110.128330 (2010).","journal-title":"J. Biol. Chem."},{"key":"5659_CR21","doi-asserted-by":"publisher","first-page":"12809","DOI":"10.1074\/jbc.M116.719377","volume":"291","author":"D Zhao","year":"2016","unstructured":"Zhao, D. et al. Zinc finger homeodomain factor Zfhx3 is essential for mammary lactogenic differentiation by maintaining prolactin signaling activity. J. Biol. Chem. 291, 12809\u201312820. https:\/\/doi.org\/10.1074\/jbc.M116.719377 (2016).","journal-title":"J. Biol. Chem."},{"key":"5659_CR22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jgg.2019.03.003","volume":"46","author":"G Ma","year":"2019","unstructured":"Ma, G. et al. Zfhx3 is essential for progesterone\/progesterone receptor signaling to drive ductal side-branching and alveologenesis in mouse mammary glands. J. Genet. genomics = Yi Chuan Xue Bao. 46, 119\u2013131. https:\/\/doi.org\/10.1016\/j.jgg.2019.03.003 (2019).","journal-title":"J. Genet. genomics = Yi Chuan Xue Bao"},{"key":"5659_CR23","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.bbrc.2012.11.009","volume":"430","author":"M Li","year":"2013","unstructured":"Li, M. et al. Upregulation of ATBF1 by progesterone-PR signaling and its functional implication in mammary epithelial cells. Biochem. Biophys. Res. Commun. 430, 358\u2013363. https:\/\/doi.org\/10.1016\/j.bbrc.2012.11.009 (2013).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"5659_CR24","doi-asserted-by":"publisher","unstructured":"Li, J. et al. KLF5 is crucial for androgen-AR signaling to transactivate genes and promote cell proliferation in prostate cancer cells. Cancers (Basel). 12 https:\/\/doi.org\/10.3390\/cancers12030748 (2020).","DOI":"10.3390\/cancers12030748"},{"key":"5659_CR25","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/ijc.31908","volume":"144","author":"Q Wu","year":"2019","unstructured":"Wu, Q. et al. CINP is a novel cofactor of KLF5 required for its role in the promotion of cell proliferation, survival and tumor growth. Int. J. Cancer. 144, 582\u2013594. https:\/\/doi.org\/10.1002\/ijc.31908 (2019).","journal-title":"Int. J. Cancer"},{"key":"5659_CR26","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1002\/imt2.85","volume":"2","author":"F Lyu","year":"2023","unstructured":"Lyu, F. et al. OmicStudio: a composable bioinformatics cloud platform with real-time feedback that can generate high-quality graphs for publication. iMeta 2, e85. https:\/\/doi.org\/10.1002\/imt2.85 (2023).","journal-title":"iMeta"},{"key":"5659_CR27","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41588-018-0318-2","volume":"51","author":"V Bhandari","year":"2019","unstructured":"Bhandari, V. et al. Molecular landmarks of tumor hypoxia across cancer types. Nat. Genet. 51, 308\u2013318. https:\/\/doi.org\/10.1038\/s41588-018-0318-2 (2019).","journal-title":"Nat. Genet."},{"key":"5659_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","volume":"18","author":"BS Taylor","year":"2010","unstructured":"Taylor, B. S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 18, 11\u201322. https:\/\/doi.org\/10.1016\/j.ccr.2010.05.026 (2010).","journal-title":"Cancer Cell."},{"key":"5659_CR29","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0095 (2012).","journal-title":"Cancer Discov"},{"key":"5659_CR30","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1. https:\/\/doi.org\/10.1126\/scisignal.2004088 (2013).","journal-title":"Sci. Signal."},{"key":"5659_CR31","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.ccr.2006.09.005","volume":"10","author":"H Hieronymus","year":"2006","unstructured":"Hieronymus, H. et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell. 10, 321\u2013330. https:\/\/doi.org\/10.1016\/j.ccr.2006.09.005 (2006).","journal-title":"Cancer Cell."},{"key":"5659_CR32","first-page":"6606","volume":"62","author":"CG Tepper","year":"2002","unstructured":"Tepper, C. G. et al. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res. 62, 6606\u20136614 (2002).","journal-title":"Cancer Res."},{"key":"5659_CR33","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.7150\/thno.41849","volume":"10","author":"Y Liao","year":"2020","unstructured":"Liao, Y. et al. Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy. Theranostics 10, 3366\u20133381. https:\/\/doi.org\/10.7150\/thno.41849 (2020).","journal-title":"Theranostics"},{"key":"5659_CR34","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.tibs.2004.12.001","volume":"30","author":"MJ Plevin","year":"2005","unstructured":"Plevin, M. J., Mills, M. M. & Ikura, M. The LxxLL motif: a multifunctional binding sequence in transcriptional regulation. Trends Biochem. Sci. 30, 66\u201369. https:\/\/doi.org\/10.1016\/j.tibs.2004.12.001 (2005).","journal-title":"Trends Biochem. Sci."},{"key":"5659_CR35","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.mce.2011.08.007","volume":"352","author":"DJ van de Wijngaart","year":"2012","unstructured":"van de Wijngaart, D. J., Dubbink, H. J., van Royen, M. E., Trapman, J. & Jenster, G. Androgen receptor coregulators: recruitment via the coactivator binding groove. Mol. Cell. Endocrinol. 352, 57\u201369. https:\/\/doi.org\/10.1016\/j.mce.2011.08.007 (2012).","journal-title":"Mol. Cell. Endocrinol."},{"key":"5659_CR36","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1097\/01.ju.0000141147.96640.76","volume":"172","author":"KH Tsui","year":"2004","unstructured":"Tsui, K. H., Wu, L., Chang, P. L., Hsieh, M. L. & Juang, H. H. Identifying the combination of the transcriptional regulatory sequences on prostate specific antigen and human glandular Kallikrein genes. J. Urol. 172, 2029\u20132034. https:\/\/doi.org\/10.1097\/01.ju.0000141147.96640.76 (2004).","journal-title":"J. Urol."},{"key":"5659_CR37","doi-asserted-by":"publisher","first-page":"7043","DOI":"10.1074\/jbc.271.12.7043","volume":"271","author":"ER Schuur","year":"1996","unstructured":"Schuur, E. R. et al. Prostate-specific antigen expression is regulated by an upstream enhancer. J. Biol. Chem. 271, 7043\u20137051. https:\/\/doi.org\/10.1074\/jbc.271.12.7043 (1996).","journal-title":"J. Biol. Chem."},{"key":"5659_CR38","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1210\/er.2009-0034","volume":"31","author":"MG Lawrence","year":"2010","unstructured":"Lawrence, M. G., Lai, J. & Clements, J. A. Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended Kallikrein locus. Endocr. Rev. 31, 407\u2013446. https:\/\/doi.org\/10.1210\/er.2009-0034 (2010).","journal-title":"Endocr. Rev."},{"key":"5659_CR39","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1210\/er.2007-0019","volume":"28","author":"HV Heemers","year":"2007","unstructured":"Heemers, H. V. & Tindall, D. J. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr. Rev. 28, 778\u2013808. https:\/\/doi.org\/10.1210\/er.2007-0019 (2007).","journal-title":"Endocr. Rev."},{"key":"5659_CR40","doi-asserted-by":"publisher","first-page":"17485","DOI":"10.1074\/jbc.272.28.17485","volume":"272","author":"N Sato","year":"1997","unstructured":"Sato, N. et al. Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1\/c-Jun in the human prostate cancer cell line LNCaP. J. Biol. Chem. 272, 17485\u201317494. https:\/\/doi.org\/10.1074\/jbc.272.28.17485 (1997).","journal-title":"J. Biol. Chem."},{"key":"5659_CR41","doi-asserted-by":"publisher","first-page":"7212","DOI":"10.1038\/sj.onc.1209705","volume":"25","author":"SY Chen","year":"2006","unstructured":"Chen, S. Y. et al. c-Jun enhancement of androgen receptor transactivation is associated with prostate cancer cell proliferation. Oncogene 25, 7212\u20137223. https:\/\/doi.org\/10.1038\/sj.onc.1209705 (2006).","journal-title":"Oncogene"},{"key":"5659_CR42","doi-asserted-by":"publisher","first-page":"24583","DOI":"10.1074\/jbc.271.40.24583","volume":"271","author":"A Bubulya","year":"1996","unstructured":"Bubulya, A., Wise, S. C., Shen, X. Q. & Burmeister, L. A. Shemshedini, L. c-Jun can mediate androgen receptor-induced transactivation. J. Biol. Chem. 271, 24583\u201324589. https:\/\/doi.org\/10.1074\/jbc.271.40.24583 (1996).","journal-title":"J. Biol. Chem."},{"key":"5659_CR43","doi-asserted-by":"publisher","first-page":"39906","DOI":"10.1074\/jbc.M307250200","volume":"278","author":"SZ Yang","year":"2003","unstructured":"Yang, S. Z. & Abdulkadir, S. A. Early growth response gene 1 modulates androgen receptor signaling in prostate carcinoma cells. J. Biol. Chem. 278, 39906\u201339911. https:\/\/doi.org\/10.1074\/jbc.M307250200 (2003).","journal-title":"J. Biol. Chem."},{"key":"5659_CR44","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/carcin\/bgi021","volume":"26","author":"H Yuan","year":"2005","unstructured":"Yuan, H., Gong, A. & Young, C. Y. Involvement of transcription factor Sp1 in quercetin-mediated inhibitory effect on the androgen receptor in human prostate cancer cells. Carcinogenesis 26, 793\u2013801. https:\/\/doi.org\/10.1093\/carcin\/bgi021 (2005).","journal-title":"Carcinogenesis"},{"key":"5659_CR45","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/aps.2014.18","volume":"36","author":"MH Tan","year":"2015","unstructured":"Tan, M. H., Li, J., Xu, H. E., Melcher, K. & Yong, E. L. Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacol. Sin. 36, 3\u201323. https:\/\/doi.org\/10.1038\/aps.2014.18 (2015).","journal-title":"Acta Pharmacol. Sin"},{"key":"5659_CR46","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1002\/pros.20483","volume":"66","author":"IV Litvinov","year":"2006","unstructured":"Litvinov, I. V. et al. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor. Prostate 66, 1329\u20131338. https:\/\/doi.org\/10.1002\/pros.20483 (2006).","journal-title":"Prostate"},{"key":"5659_CR47","doi-asserted-by":"publisher","first-page":"12182","DOI":"10.1073\/pnas.0804700105","volume":"105","author":"Y Niu","year":"2008","unstructured":"Niu, Y. et al. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc. Natl. Acad. Sci. U S A. 105, 12182\u201312187. https:\/\/doi.org\/10.1073\/pnas.0804700105 (2008).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"5659_CR48","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.celrep.2016.09.064","volume":"17","author":"S Gao","year":"2016","unstructured":"Gao, S. et al. Androgen receptor tumor suppressor function is mediated by recruitment of retinoblastoma protein. Cell. Rep. 17, 966\u2013976. https:\/\/doi.org\/10.1016\/j.celrep.2016.09.064 (2016).","journal-title":"Cell. Rep."},{"key":"5659_CR49","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1530\/ERC-13-0293","volume":"21","author":"G Daniels","year":"2014","unstructured":"Daniels, G. et al. TBLR1 as an androgen receptor (AR) coactivator selectively activates AR target genes to inhibit prostate cancer growth. Endocr. Relat. Cancer. 21, 127\u2013142. https:\/\/doi.org\/10.1530\/ERC-13-0293 (2014).","journal-title":"Endocr. Relat. Cancer"},{"key":"5659_CR50","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.ccr.2011.09.001","volume":"20","author":"C Cai","year":"2011","unstructured":"Cai, C. et al. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell. 20, 457\u2013471. https:\/\/doi.org\/10.1016\/j.ccr.2011.09.001 (2011).","journal-title":"Cancer Cell."},{"key":"5659_CR51","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ajpath.2023.12.003","volume":"194","author":"Z Culig","year":"2024","unstructured":"Culig, Z. & Puhr, M. Androgen Receptor-Interacting proteins in prostate Cancer development and therapy resistance. Am. J. Pathol. 194, 324\u2013334. https:\/\/doi.org\/10.1016\/j.ajpath.2023.12.003 (2024).","journal-title":"Am. J. Pathol."},{"key":"5659_CR52","doi-asserted-by":"publisher","first-page":"31528","DOI":"10.1074\/jbc.273.47.31528","volume":"273","author":"J Lu","year":"1998","unstructured":"Lu, J. & Danielsen, M. Differential regulation of androgen and glucocorticoid receptors by retinoblastoma protein. J. Biol. Chem. 273, 31528\u201331533. https:\/\/doi.org\/10.1074\/jbc.273.47.31528 (1998).","journal-title":"J. Biol. Chem."},{"key":"5659_CR53","doi-asserted-by":"publisher","first-page":"11256","DOI":"10.1073\/pnas.190353897","volume":"97","author":"S Yeh","year":"2000","unstructured":"Yeh, S. et al. Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells. Proc. Natl. Acad. Sci. U S A. 97, 11256\u201311261. https:\/\/doi.org\/10.1073\/pnas.190353897 (2000).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"5659_CR54","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/s0022-5347(17)40211-4","volume":"143","author":"WH Cooner","year":"1990","unstructured":"Cooner, W. H. et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J. Urol. 143, 1146\u20131152. https:\/\/doi.org\/10.1016\/s0022-5347(17)40211-4 (1990). discussion 1152\u2009\u2013\u20091144.","journal-title":"J. Urol."},{"key":"5659_CR55","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1056\/NEJMoa031918","volume":"350","author":"IM Thompson","year":"2004","unstructured":"Thompson, I. M. et al. Prevalence of prostate cancer among men with a prostate-specific antigen level\u2009<\u2009or =\u20094.0 Ng per milliliter. N Engl. J. Med. 350, 2239\u20132246. https:\/\/doi.org\/10.1056\/NEJMoa031918 (2004).","journal-title":"N Engl. J. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05659-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05659-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05659-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T11:21:24Z","timestamp":1751368884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05659-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5659"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-05659-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"11 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics, consent to participate, and consent to publish declarations"}}],"article-number":"20931"}}